Morgan Stanley (MS) Reports Q3 Earnings: What Key Metrics Have to Say

15.10.25 15:30 Uhr

Werte in diesem Artikel
Aktien

138,96 EUR 5,24 EUR 3,92%

Indizes

PKT PKT

17.955,8 PKT 127,5 PKT 0,72%

3.326,8 PKT 16,3 PKT 0,49%

6.671,1 PKT 26,8 PKT 0,40%

Morgan Stanley (MS) reported $18.22 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 18.5%. EPS of $2.80 for the same period compares to $1.88 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $16.45 billion, representing a surprise of +10.8%. The company delivered an EPS surprise of +34.62%, with the consensus EPS estimate being $2.08.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Morgan Stanley performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Book value per common share: $62.98 compared to the $62.22 average estimate based on four analysts.Return on average common equity: 18% versus 12.9% estimated by four analysts on average.Wealth Management - Total client assets: $7,054.00 billion compared to the $6,479.11 billion average estimate based on two analysts.Total assets under management: $1,807.00 billion compared to the $1,731.11 billion average estimate based on two analysts.Revenues- Investment banking: $2.27 billion versus the three-analyst average estimate of $1.79 billion. The reported number represents a year-over-year change of +42.5%.Revenues- Commissions and fees: $1.47 billion compared to the $1.39 billion average estimate based on three analysts. The reported number represents a change of +13.8% year over year.Revenues- Institutional securities- Sales and Trading- Fixed income: $2.17 billion compared to the $2.06 billion average estimate based on three analysts. The reported number represents a change of +8.3% year over year.Revenues- Institutional securities- Sales and trading- Equity: $4.12 billion compared to the $3.22 billion average estimate based on three analysts. The reported number represents a change of +35.2% year over year.Revenues- Institutional securities- Other: $130 million versus $230.43 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -57.2% change.Revenues- Institutional securities- Investment banking: $2.11 billion compared to the $1.52 billion average estimate based on three analysts. The reported number represents a change of +44.1% year over year.Net revenues- Investment Management: $1.65 billion versus $1.52 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +13.5% change.Net revenues- Institutional Securities: $8.52 billion versus $7.03 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +25.1% change.View all Key Company Metrics for Morgan Stanley here>>>Shares of Morgan Stanley have returned -0.3% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Morgan Stanley (MS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Morgan Stanley und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf CGI Group

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf CGI Group

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Morgan Stanley

Wer­bung

Analysen zu Morgan Stanley

DatumRatingAnalyst
16.07.2024Morgan Stanley NeutralUBS AG
19.04.2023Morgan Stanley BuyJefferies & Company Inc.
14.04.2022Morgan Stanley BuyGoldman Sachs Group Inc.
28.09.2021Morgan Stanley HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
20.04.2021Morgan Stanley kaufenCredit Suisse Group
DatumRatingAnalyst
19.04.2023Morgan Stanley BuyJefferies & Company Inc.
14.04.2022Morgan Stanley BuyGoldman Sachs Group Inc.
20.04.2021Morgan Stanley kaufenCredit Suisse Group
15.10.2020Morgan Stanley OutperformRBC Capital Markets
05.10.2020Morgan Stanley OutperformRBC Capital Markets
DatumRatingAnalyst
16.07.2024Morgan Stanley NeutralUBS AG
28.09.2021Morgan Stanley HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
02.04.2020Morgan Stanley neutralDeutsche Bank AG
21.01.2020Morgan Stanley NeutralCitigroup Corp.
04.04.2019Morgan Stanley HoldHSBC
DatumRatingAnalyst
20.01.2016Morgan Stanley SellSociété Générale Group S.A. (SG)
25.07.2011Morgan Stanley underperformRBC Capital Markets
02.10.2009Morgan Stanley underperformCalyon Securities Inc.
31.08.2005Morgan Stanley underweightPrudential Financial
28.07.2005Morgan Stanley underweightPrudential Financial

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Morgan Stanley nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen